Mastering variation: Variance components and personalised medicine

Statistics in Medicine

Volumn 35, Issue 7, 2016, Pages 966-977

  Senn, Stephen ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

Components of variation; Cross over trials; N of 1 trials; Personalised medicine; Random effects

Indexed keywords

ARTICLE; ASTHMA; CLINICAL PRACTICE; FORCED EXPIRATORY VOLUME; GENETIC VARIABILITY; HEALTH CARE POLICY; HUMAN; MEDICAL DECISION MAKING; METHODOLOGY; PERSONALIZED MEDICINE; STUDY DESIGN; TONSILLECTOMY; TREATMENT RESPONSE; VARIANCE; ANALYSIS OF VARIANCE; BIOSTATISTICS; CLINICAL TRIAL (TOPIC); COMPUTER GRAPHICS; COMPUTER SIMULATION; CROSSOVER PROCEDURE; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA; UTILIZATION;

ANALYSIS OF VARIANCE; ASTHMA; BIOSTATISTICS; CLINICAL TRIALS AS TOPIC; COMPUTER GRAPHICS; COMPUTER SIMULATION; CROSS-OVER STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; PRECISION MEDICINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TONSILLECTOMY;

EID: 84959474251     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6739     Document Type: Article

References (54)

1. Poincaré H. Calcul des Probabilités (2nd edn). Gauthier-Villars et Cie: Paris, 1912.
2. Senn SJ. Individual therapy: New dawn or false dawn. Drug Information Journal 2001; 35:1479-1494.
3. Senn SJ. Individual response to treatment: is it a valid assumption? British Medical Journal 2004; 329:966-968.
4. Keller JL, Guyatt GH, Roberts RS, Adachi JD, Rosenbloom D. An N of 1 service: applying the scientific method in clinical practice. Scandinavian Journal of Gastroenterology 1988; 23(S147):22-29.
5. Senn SJ. Suspended judgment n-of-1 trials. Controlled Clinical Trials 1993; 14:1-5.
6. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8:283-289.
7. Food and Drug Administration. Paving the way for personalized medicine: FDA's role in a new era of medical product development. In Paving the Way for Personalized Medicine: FDA's Role in a New Era of Medical Product Development, U.S. Department of Health and Human Services (ed). Food and Drug Administration, Silver Spring, MD: City, 2013.
8. Cancer Research UK, http://www.cancerresearchuk.org/cancer-info/cancerstats/types/ Date accessed 3 May 2015
9. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends in Molecular Medicine 2001; 7:201-204.
10. Physicians' Desk Reference. Physicians' Desk Reference, Medical Economics (ed). Medical Economics Company: Montvale, NJ, 2000.
11. Senn S. A note regarding 'random effects'. Statistics in Medicine 2014; 33:2876-2877.
12. Deming WE. Out of the Crisis. MIT press: Cambridge, MA, 1982.
13. Campbell MK, Mollison J, Grimshaw JM. Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Statistics in Medicine 2001; 20:391-399.
14. Fleiss JL. Analysis of data from multiclinic trials. Controlled Clinical Trials 1986; 7:267-275.
15. Grizzle JE. Analysis of data from multiclinic trials. Controlled Clinical Trials 1987; 8:392-393.
16. Jones B, Teather D, Wang J, Lewis JA. A comparison of various estimators of a treatment difference for a multi-centre clinical trial. Statistics in Medicine 1998; 17:1767-1777 discussion 1799-1800.
17. Senn SJ. Some controversies in planning and analysing multi-centre trials. Statistics in Medicine 1998; 17:1753-1765; discussion 1799-1800.
18. Gallo P. Center-weighting issues in multicenter clinical trials. Journal of biopharmaceutical statistics 2001; 10:145-163.
19. Fedorov V, Jones B. The design of multicentre trials. Statistical Methods in Medical Research 2005; 14:205-248.
20. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23N-of-1 randomized controlled trials. The Journal of rheumatology 1991; 18:447-451.
21. Cox DR. Planning of Experiments. John Wiley: New York, 1958.
22. Rosenberger WF, Lachin JM. Randomization in Clinical Trials: Theory and Practice. Wiley: New York, 2002.
23. Bennett JH. Statistical Inference and Analysis Selected Correspondence of R.A. Fisher. Oxford University Press: Oxford, 1990.
24. Preece DA. T is for trouble (and textbooks): a critique of some examples of the paired-samples t-test. The Statistician 1982; 31:169-195.
25. Cushny AR, Peebles AR. The action of optimal isomers. II. Hyoscines. Journal of Physiology 1905; 32:501-510.
26. Senn SJ, Richardson W. The first t-test. Statistics in Medicine 1994; 13:785-803.
27. Student. The probable error of a mean. Biometrika 1908; 6:1-25.
28. Senn S, Rolfe K, Julious SA. Investigating variability in patient response to treatment - a case study from a replicate cross-over study. Statistical Methods in Medical Research 2011; 20:657-666.
29. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie W-R, Hildebrand WH, Mardis ER. A Dendritic Cell Vaccine Increases the Breadth and Diversity of Melanoma Neoantigen-Specific T Cells. Science (New York NY), 2015.
30. Schork NJ. Personalized medicine: time for one-person trials. Nature 2015; 520:609-611.
31. Senn S, Julious S. Measurement in clinical trials: a neglected issue for statisticians? Statistics in Medicine 2009; 28:3189-3209.
32. Senn SJ. Disappointing dichotomies. Pharmaceutical statistics 2003; 2:239-240.
33. Senn SJ. Three things every medical writer should know about statistics. The Write Stuff 2009; 18:159-162.
34. Senn SJ. Cross-over Trials in Clinical Research (Second edn). Wiley: Chichester, 2002.
35. de González AB, Cox DR. Interpretation of interaction: a review. The Annals of Applied Statistics 2007; 1:371-385.
36. Cox DR. Interaction. International Statistical Review/Revue Internationale de Statistique 1984; 52:1-24.
37. Senn SJ. Added values: controversies concerning randomization and additivity in clinical trials. Statistics in Medicine 2004; 23:3729-3753.
38. Box GE, Cox DR. An analysis of transformations. Journal of the Royal Statistical Society. Series B (Methodological) 1964:211-252.
39. Lones MA, Smith SL, Alty JE, Lacy SE, Possin KL, Jamieson DS, Tyrrell AM. Evolving classifiers to recognize the movement characteristics of Parkinson's disease patients. Evolutionary Computation, IEEE Transactions on 2014; 18:559-576.
40. Lane PW, Nelder JA. Analysis of covariance and standardization as instances of prediction. Biometrics 1982; 38:613-621.
41. Greenlaw N. Constructing Appropriate Models for Meta-analyses. University of Glasgow: Glasgow, 2009.
42. Engels EA, Schmid CH, Terrin N, Olkin I, Lau J. Heterogeneity and statistical significance in meta-analysis: an empirical study of 125 meta-analyses. Statistics in Medicine 2000; 19:1707-1728.
43. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. British Medical Journal 1995; 311:1356-1359.
44. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. American Journal of Epidemiology 1980; 112:467-470.
45. Sjolander A, Lee W, Kallberg H, Pawitan Y. Bounds on sufficient-cause interaction. European Journal of Epidemiology 2014; 29:813-820.
46. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Sovik O, Polak M, Hattersley AT. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. The New England Journal of Medicine 2006; 355:467-477.
47. Bouckaert A, Mouchart M. Sure outcomes of random events: a model for clinical trials. Statistics in Medicine 2001; 20:521-543.
48. Goldacre M, Yeates D, Gill L, Hall N, Davidson M. Tonsillectomy in people aged under 15 in England. Unit of Health Care Epidemiology, University of Oxford: Oxford, 2013; 98.
49. Wennberg JE. Time to tackle unwarranted variations in practice. BMJ 2011; 342.
50. James BC, Savitz LA. How Intermountain trimmed health care costs through robust quality improvement efforts. Health Affairs 2011; 30:1185-1191.
51. Senn SJ. Statistical Issues in Drug Development. Wiley: Hoboken, 2007.
52. James JE. Personalised medicine, disease prevention, and the inverse care law: more harm than benefit? European Journal of Epidemiology 2014; 29:383-390.
53. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England Journal of Medicine 2000; 343:78-85.
54. Smith GD. Epidemiology, epigenetics and the 'Gloomy Prospect': embracing randomness in population health research and practice. International Journal of Epidemiology 2011; 40:537-562.